ArticleHemaSphere2026

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Denis Pinkle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.